23andMe, Inc. Appoints Ruby Gadelrab Vice President Of Commercial Marketing

MOUNTAIN VIEW, Calif., Oct. 20, 2014 /PRNewswire/ -- 23andMe, the leading personal genetics company, today announced the appointment of Ruby Gadelrab as vice president, commercial marketing. Gadelrab will oversee the global marketing efforts for the company's industry and academic collaborations.

"Ruby brings an incredible depth of knowledge and experience to 23andMe through an impressive track record with some of the industry's leading global genomics and biotech companies," said Andy Page, President of 23andMe. "Her insight and ability to engage and connect with genetics-based researchers will strengthen 23andMe's capabilities in a crucial area of success."

Before joining 23andMe, Gadelrab served as head of marketing and commercial development at Invitae Corporation, a genetic information company. Prior to joining Invitae, Gadelrab worked at Affymetrix, Inc., where she most recently served as head of international marketing and clinical development. Gadelrab started her career in genomics at a number of well-known companies, including Life Technologies, Dharmacon and AbGene.

"23andMe is at the forefront of enabling genetic research that can help accelerate the pace of disease and drug discoveries," said Gadelrab. "I'm excited to join 23andMe at this important juncture as the company continues to grow its customer base and explore new commercial and research partnerships."

Gadelrab holds a Bachelor of Science in Molecular Biology from the University College London.

About 23andMe
23andMe, Inc. is the leading personal genetics company dedicated to helping people access, understand and benefit from the human genome. The company's Personal Genome Service® enables individuals to gain deeper insights into their genetics and ancestry. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. More information is available at www.23andme.com. 23andMe's health reports are not cleared by the FDA. US customers may purchase 23andMe's ancestry-only product.

Jackie Kahn
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/23andme-appoints-ruby-gadelrab-vice-president-of-commercial-marketing-549230951.html

SOURCE 23andMe

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.